Urinary trypsin inhibitor attenuates liver enzyme elevation after liver resection

Cheol-Won Jeong, Cha-Sup Lee, Seong-Heon Lee, Hye Jin Jeung, Sang-Hyun Kwak, Cheol-Won Jeong, Cha-Sup Lee, Seong-Heon Lee, Hye Jin Jeung, Sang-Hyun Kwak

Abstract

Background: Urinary trypsin inhibitors (UTI) have been widely used for the treatment of diseases including disseminated intravascular coagulation, shock, and pancreatitis. Since UTI synthesis is likely to be reduced in patients who have undergone liver resection, the incidence of inflammatory reactions may be increasing accordingly. For such patients, the liver enzyme increases after the operation can reflect liver damage. The purpose of this study was to examine if ulinastatin can inhibit liver enzyme increases after liver resection.

Methods: After receiving Institutional Review Board approval, a retrospective chart review was performed on 201 patients who underwent hepatic resection from 2006 to 2010. We divided the records into the control (n = 69) and ulinastatin (n = 132) groups according to the use of intraoperative ulinastatin and compared the preoperative and postoperative laboratory test results. The number of patients who had > 400 U/L elevation of aspartate transaminase (AST) level after surgery was compared between the 2 groups.

Results: The mean AST, alanine transaminase (ALT), and total bilirubin levels after liver resection were significantly lower in the ulinastatin group than in the control group. The number of patients who showed an AST > 400 U/L after liver resection was significantly higher in the control group (odds ratio = 3.02).

Conclusions: Ulinastatin attenuates the elevation of hepatic enzymes and bilirubin after liver resection.

Keywords: Hepatectomy; Liver function test; Retrospective study; Ulinastatin.

References

    1. Schneider PD. Preoperative assessment of liver function. Surg Clin North Am. 2004;84:355–373.
    1. Ishikawa M, Nishioka M, Hanaki N, Miyauchi T, Kashiwagi Y, Miki H. Hepatic resection induces a shift in the Th 1/2 balance toward Th 2 and produces hypermetabolic and hyperhemodynamic states. Hepatogastroenterology. 2004;51:1422–1427.
    1. Iwai H, Nagaki M, Naito T, Ishiki Y, Murakami N, Sugihara J, et al. Removal of endotoxin and cytokines by plasma exchange in patients with acute hepatic failure. Crit Care Med. 1998;26:873–876.
    1. Sauer A, Hartung T, Aigner J, Wendel A. Endotoxin-inducible granulocyte-mediated hepatocytotoxicity requires adhesion and serine protease release. J Leukoc Biol. 1996;60:633–643.
    1. Yano T, Anraku S, Nakayama R, Ushijima K. Neuroprotective effect of urinary trypsin inhibitor against focal cerebral ischemia-reperfusion injury in rats. Anesthesiology. 2003;98:465–473.
    1. Kim SJ, Yoo KY, Jeong CW, Kim WM, Lee HK, Bae HB, et al. Urinary trypsin inhibitors afford cardioprotective effects through activation of PI3K-Akt and ERK signal transduction and inhibition of p38 MAPK and JNK. Cardiology. 2009;114:264–270.
    1. Chen CC, Liu ZM, Wang HH, He W, Wang Y, Wu WD. Effects of ulinastatin on renal ischemia-reperfusion injury in rats. Acta Pharmacol Sin. 2004;25:1334–1340.
    1. Park JH, Kwak SH, Jeong CW, Bae HB, Kim SJ. Effect of ulinastatin on cytokine reaction during gastrectomy. Korean J Anesthesiol. 2010;58:334–337.
    1. Choi SJ, Gwak MS, Kim MH, Yang M, Ko JS, Hahm TS, et al. Differences of perioperative liver function, transfusion, and complications according to the type of hepatectomy in living donors. Transpl Int. 2005;18:548–555.
    1. Whitehead MW, Hawkes ND, Hainsworth I, Kingham JG. A prospective study of the causes of notably raised aspartate aminotransferase of liver origin. Gut. 1999;45:129–133.
    1. Chiarla C, Giovannini I, Giuliante F, Vellone M, Ardito F, Masi A, et al. Plasma bilirubin correlations in non-obstructive cholestasis after partial hepatectomy. Clin Chem Lab Med. 2008;46:1598–1601.
    1. Schindl MJ, Redhead DN, Fearon KC, Garden OJ, Wigmore SJ. The value of residual liver volume as a predictor of hepatic dysfunction and infection after major liver resection. Gut. 2005;54:289–296.
    1. Mullin EJ, Metcalfe MS, Maddern GJ. How much liver resection is too much? Am J Surg. 2005;190:87–97.
    1. Truant S, Oberlin O, Sergent G, Lebuffe G, Gambiez L, Ernst O, et al. Remnant liver volume to body weight ratio > or =0.5%: A new cut-off to estimate postoperative risks after extended resection in noncirrhotic liver. J Am Coll Surg. 2007;204:22–33.
    1. Xu L, Ren B, Li M, Jiang F, Zhanng Z, Hu J. Ulinastatin suppresses systemic inflammatory response following lung ischemia-reperfusion injury in rats. Transplant Proc. 2008;40:1310–1311.
    1. Tani T, Aoki H, Yoshioka T, Lin KJ, Kodama M. Treatment of septic shock with a protease inhibitor in a canine model: a prospective, randomized, controlled trial. Crit Care Med. 1993;21:925–930.
    1. Nishiyama T, Yokoyama T, Yamashita K. Effects of a protease inhibitor, ulinastatin, on coagulation and fibrinolysis in abdominal surgery. J Anesth. 2006;20:179–182.
    1. Park KH, Lee KH, Kim H, Hwang SO. The anti-inflammatory effects of ulinastatin in trauma patients with hemorrhagic shock. J Korean Med Sci. 2010;25:128–134.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi